Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7115578B2 · kind B2 · utility
0Cited by
7References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2004 |
| Grant date | Oct 3, 2006 |
| Priority date | — |
| Expiry date | Aug 4, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula Vare disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.